

## PHARMACEUTICALS

12 August 2025

### Monthly IPM dose

- IPM for July'25 grew by 7.9% in value and 0.4% in unit. On a MAT basis, growth stood at 7.4% in value and 0.4% in unit
- Cardiac led therapy growth with 14% in value and 6.2% in volume; Gastro reported the lowest growth at 4% value and -4.1% volume
- IPM expected to continue growing at a similar range of 7-9%. Our preferred picks from the domestic space are SUN and BOOT

Foram Parekh  
 research@bobcaps.in

**IPM reported strong growth:** IPM for July'25 grew by 7.9% in value and 0.4% in volume. to Rs 205bn. IPM growth on MAT basis growth stood at 7.4% in value and 0.4% unit growth to Rs 2,308 bn. IPM growth of 7.9% on MTH basis was driven by 5.6% value growth, 2.5% new product launches and -0.2% volume growth. This is the 7<sup>th</sup> consecutive month in CY25 where IPM growth is driven by price hike and new product launches and volume growth have been negligible.

**Acute therapies reported lower value growth over Chronic therapies:** On MTH basis, acute therapies like Anti-Infectives reported 6% value growth and -2.3% volume growth, Respiratory reported 9.2% value growth and 5.7% volume growth, while Pain grew 5.8% (value) and -3.1% (volume). Amongst Chronic therapies, Cardiac reported 14.1% value growth and 6.2% volume growth, Derma grew 6.6% in value and -2.9% in volume and growth for CNS stood at 8.3% (value) and -1.3% (volume).

**Large-sized companies' performance steady over mid/small size:** On MTH basis, large-sized companies like SUN continue to report 13% value growth and 4% volume growth; for Abbott (including subsidiaries), growth came at 8% (value) and 2% (volume), and Mankind grew 9% in value and 4% in volume. Amongst mid-sized companies, GSK reported 7% value growth and 0% volume growth, Emcure 5% and 9% in value and volume, and Glenmark reported 13% value growth and -2% volume growth. Amongst the small sized, Alembic reported -4% value growth and -10% volume growth, Eris reported 7% value growth and 1% volume growth, Ajanta reported 14% value growth and 8% volume growth.

**Steady IPM growth to continue at current rate** IPM is expected to grow 7–9% in CY2025, driven by price hike of 1.74% for NLEM products, 5–7% hikes on non-NLEM products, and new launches which is increasing as molecules like Empagliflozin went LOE and is expected to rise further as GLP-1 molecule Semaglutide nears expiry. **Preferred picks** are Sun due to leading position in the IPM with 8.5% market share driven by leadership across 13 categories and BOOT due to focus on top 20 products contributing ~80% of the core sales.



**Fig 1 – Therapy wise break up on MTH basis**

July'25	IPM	Cardiac	Anti-Infective	Gastro	Anti-Diabetes	Vitamins/Nutrition	Respiratory	Pain/Anal	Derma	Neuro/CNS	Gynaec	Blood related	Anti-Neoplas	Opthal	Hormones	Urology
New Product	2.5	1.3	0.8	2.4	6.3	2.6	2.9	1.9	2.7	1.9	3.2	4.7	1.2	1.4	1.9	2.6
Price growth	5.6	7	3.7	6.7	2.7	6	8	5.8	6	6.3	4.3	7.2	(0.6)	4.9	2.9	8.1
Volume growth	(0.2)	5.8	1.5	(5.1)	0.1	(4)	(1.7)	(1.9)	(2.1)	0.1	(2.6)	(1)	8.6	(0.7)	3.3	4.2

Source: BOBCAPS Research, Pharmarack

From the above table, we see Anti Diabetes having the highest new product launches as many companies have launched the generic version of Empaglifozin post LoE. Due to LoE, price growth is lower than IPM growth. Gastro witnessed steep volume decline of 5%, followed by Vitamins with 4% volume decline while Anti Neoplast witnessed steep volume rise of 8.6%, followed by Cardiac with 5.8% volume growth. Mostly, all therapies witnessed price hikes above the IPM price hike, barring therapies like Anti-Infectives with 3.7%, Anti Diabetes with 2.7%, Gynaec with 4.3%, Anti Neoplast with -0.6%, Opthal with 4.9% and Hormones with 2.9% price hike.


**Fig 2 – Therapy wise breakup on MAT basis**

MAT July'25	IPM	Cardiac	Anti-Infective	Gastro	Anti-Diabetes	Vitamins/Nutrition	Respiratory	Pain/Anal	Derma	Neuro/CNS	Gynaec	Blood related	Anti-Neoplas	Opthal	Hormones	Urology
New Product	2.2	1.1	0.8	2.5	3.3	2.9	2.1	1.8	2.7	2.1	2.6	4.1	2	1.8	2.6	2.8
Price growth	5.3	6.4	3.7	6.4	4.3	6	6.4	5.8	5.8	6.1	3.8	4.5	0.5	4.3	2.2	7.2
Volume growth	(0.1)	3.2	0.8	(1.5)	0.1	(2.9)	(4.6)	(0.6)	0.5	0	(5.2)	0.9	8.1	(1)	4.6	5

Source: BOBCAPS Research, Pharmarack

From the above table, on a MAT basis, we see Blood-related having the highest new product launch growth at 4%, followed by Anti-Diabetes with 3.3% vs IPM growth of 2.2%. Amongst price growth, Urology reported the highest price growth of 7.2%, followed by Gastro/Cardiac growth of 6.4% vs IPM growth of 5.3% and volume -wise growth. Gynaec underperformed IPM at 5.2% while Anti Neoplast surpassed at 8.1%.

**Fig 3 – Acute - Chronic split**



Source: BOBCAPS Research, Pharmarack

### Acute therapy performance

During the month Acute segment grew by 6%, contributing 44% of the IPM. The growth was driven by Augmentin (GSK) sustaining its leadership position, outpacing the broader acute market and reporting exceptional double-digit growth in both value and volume terms. Company wise, GSK and Torrent advanced by one rank each, while Glenmark surged ahead by two positions with both Torrent and Glenmark registering strong double-digit value growth.

**Fig 4 – Performance of companies in Acute segment**

RANK	CORPORATE	MS% G/L	VAL GR%	UNIT GR%	RANK	CORPORATE	MS% G/L	VAL GR%	UNIT GR%
OVERALL			11%	4%	OVERALL			11%	4%
1	SUN*	0.3%	13%	5%	11	EMCURE*	0.1%	15%	26%
2	ABBOTT*	-0.2%	8%	6%	12	MACLEODS	0.1%	15.9%	-1%
3	CIPLA	-0.4%	4%	-1%	13*	DR. REDDYS	0.0%	12%	2%
4	INTAS	0.1%	12%	0%	14	▲ MICRO	0.0%	13%	10%
5	LUPIN	-0.1%	10%	7%	15	▼ ERIS LS	-0.2%	0%	0%
6	▲ MANKIND*	0.4%	20%	10%	16	IPCA	0.0%	10%	0%
7	▼ TORRENT	0.1%	13%	3%	17	JB CHEMICALS	0.1%	21%	4%
8	▼ USV	0.1%	13%	5%	18	ALKEM*	0.1%	20%	15%
9	ZYDUS*	-0.2%	5%	-7%	19	ARISTO	0.1%	16%	7%
10	GI FENMARK	0.1%	14%	6%	20	AJANTA	0.0%	10%	6%

Source: BOBCAPS Research, Pharमारack

### Chronic therapy performance

During the month, Chronic segment grew by 10.8%, contributing 34% of the IPM. The growth was driven by Power brands in chronic therapies such as Thyronorm (Abbott), Cilacar (JB Chemicals), Telma (Glenmark), Lantus (Sanofi), and Ecosprin AV (USV), all ranking among the top 10 brands; delivering exceptional value and volume growth. Company-wise, Mankind advanced by two ranks and Micro by one, with both posting double-digit growth in value and volume.

**Fig 5 – Performance of companies in Chronic segment**

RANK	CORPORATE	MS% G/L	VAL GR%	UNIT GR%	RANK	CORPORATE	MS% G/L	VAL GR%	UNIT GR%
OVERALL			11%	4%	OVERALL			11%	4%
1	SUN*	0.3%	13%	5%	11	EMCURE*	0.1%	15%	26%
2	ABBOTT*	-0.2%	8%	6%	12	MACLEODS	0.1%	15.9%	-1%
3	CIPLA	-0.4%	4%	-1%	13	DR. REDDYS	0.0%	12%	2%
4	INTAS	0.1%	12%	0%	14	▲ MICRO	0.0%	13%	10%
5	LUPIN	-0.1%	10%	7%	15	▼ ERIS LS	-0.2%	0%	0%
6	▲ MANKIND*	0.4%	20%	10%	16	IPCA	0.0%	10%	0%
7	▼ TORRENT	0.1%	13%	3%	17	JB CHEMICALS	0.1%	21%	4%
8	▼ USV	0.1%	13%	5%	18	ALKEM*	0.1%	20%	15%
9	ZYDUS*	-0.2%	5%	-7%	19	ARISTO	0.1%	16%	7%
10	GLENMARK	0.1%	14%	6%	20	AJANTA	0.0%	10%	6%

Source: BOBCAPS Research, Pharमारack

**Fig 6 – Therapy-wise IPM growth**

SUPER GROUP	MAT Jul'25					MTH Jul'25				
	SALES	VAL	CONT%	VAL GR%	UNIT GR%	SALES	VAL	CONT%	VAL GR%	UNIT GR%
IPM	230867		100%	7.4%	0.4%	20494		100%	7.9%	0.4%
CARDIAC	31052		13%	10.7%	3.0%	2837		14%	14.1%	6.2%
GASTRO INTESTINAL	28145		12%	7.4%	1.2%	2571		13%	4.0%	-4.1%
ANTI-INFECTIVES	27040		12%	5.3%	-1.9%	2321		11%	6.1%	-2.3%
ANTI DIABETIC	20949		9%	7.8%	3.8%	1894		9%	9.2%	6.4%
VIT / MIN / NUT	20697		9%	5.9%	-2.5%	1879		9%	4.7%	-2.4%
RESPIRATORY	17353		8%	3.8%	-0.8%	1288		6%	9.2%	5.7%
PAIN / ANALGESICS	16000		7%	7.0%	-2.1%	1429		7%	5.8%	-3.1%
NEURO / CNS	15345		7%	8.2%	0.4%	1349		7%	8.3%	-1.3%
DERMA	15048		7%	9.0%	1.3%	1350		7%	6.6%	-2.9%
GYNAECOLOGICAL	7238		3%	1.2%	-3.2%	671		3%	5.0%	-2.3%
BLOOD RELATED	7136		3%	9.5%	-1.8%	670		3%	10.9%	0.6%
ANTI-NEOPLASTICS	5415		2%	10.6%	4.5%	479		2%	9.1%	7.0%
OPHTHAL / OTOLOGICALS	4378		2%	5.1%	-3.1%	391		2%	5.6%	-2.0%
UROLOGY	3814		2%	14.9%	5.6%	351		2%	14.8%	4.8%
HORMONES	3790		2%	9.3%	7.8%	324		2%	8.1%	15.3%
VACCINES	2081		1%	6.4%	-9.4%	200		1%	14.1%	-3.8%
OTHERS	1878		1%	12.4%	12.2%	179		1%	18.6%	11.0%
STOMATOLOGICALS	1606		1%	9.9%	1.9%	145		1%	7.5%	-0.2%
SEX STIMULANTS / REJUV	1246		1%	6.6%	-0.6%	109		1%	2.9%	-4.8%
ANTI MALARIALS	656		0%	5.6%	7.3%	59		0%	8.3%	13.4%

Source: Company, BOBCAPS Research, Pharmarack

**Fig 7 – Top 20 company-wise data**

CORPORATE	MAT Jul'25					MTH Jul'25						
	SALES	VAL	RANK	CONT%	VAL GR%	UNIT GR%	SALES	VAL	RANK	CONT%	VAL GR%	UNIT GR%
IPM	230867			100%	7.4%	0.4%	20494			100%	7.9%	0.4%
SUN*	19328		1	8.4%	11.5%	2.0%	1749		1	8.5%	12.6%	4.2%
ABBOTT*	13628		2	5.9%	8.2%	1.8%	1202		2	5.9%	7.7%	2.2%
MANKIND*	13216		3	5.7%	7.6%	3.2%	1198		3	5.8%	9.3%	4.3%
CIPLA	11904		4	5.2%	7.1%	0.6%	906		4	4.4%	5.1%	-1.0%
ALKEM*	9474		5	4.1%	7.7%	1.2%	838		5	4.1%	11.0%	1.3%
INTAS	8929		6	3.9%	11.0%	4.7%	765		6	3.7%	11.2%	3.4%
TORRENT	8414		7	3.6%	11.7%	2.2%	762		7	3.7%	11.1%	1.7%
LUPIN	8009		8	3.5%	6.8%	-1.5%	723		8	3.5%	6.6%	-2.9%
ZYDUS*	7363		9	3.2%	6.9%	-4.3%	655		9	3.2%	10.3%	1.1%
DR. REDDYS	7141		10	3.1%	9.0%	0.9%	635		10	3.1%	10.8%	1.2%
MACLEODS	6921		11	3.0%	3.6%	-1.6%	603		11	2.9%	9.1%	1.7%
ARISTO	6499		12	2.8%	3.8%	-1.1%	560		12	2.7%	6.1%	-1.3%
EMCURE*	6047		13	2.6%	5.1%	2.4%	553		13	2.7%	4.7%	9.3%
GSK	4903		14	2.1%	7.3%	0.7%	434		14	2.1%	7.3%	-0.2%
GLENMARK	4717		15	2.0%	10.6%	0.9%	432		15	2.1%	12.9%	-1.7%
USV	4599		16	2.0%	6.7%	2.7%	410		16	2.0%	11.0%	4.8%
IPCA	4442		17	1.9%	8.9%	-0.6%	400		17	2.0%	10.2%	3.6%
MICRO	3763		18	1.6%	7.3%	0.6%	340		18	1.7%	4.5%	-3.5%
PFIZER*	3119		19	1.4%	1.7%	-5.7%	277		19	1.4%	2.0%	-6.1%
ERIS LS	3091		20	1.3%	6.0%	1.6%	267		20	1.3%	7.2%	1.4%

Source: BOBCAPS Research, Pharmarack

**Fig 8 – Next 20 company-wise data**

CORPORATE	MAT Jul'25					MTH Jul'25						
	SALES	VAL	RANK	CONT%	VAL GR%	UNIT GR%	SALES	VAL	RANK	CONT%	VAL GR%	UNIT GR%
IPM	230867			100%	7.4%	0.4%	20494			100%	7.9%	0.4%
ALEMBIC	2847		21	1.2%	2.3%	-3.8%	243		21	1.2%	-3.8%	-10.1%
JB CHEMICALS	2337		22	1.0%	8.0%	-8.5%	227		22	1.1%	9.2%	-10.8%
FDC	2007		23	0.9%	7.3%	10.8%	179		23	0.9%	7.3%	4.8%
SANOFI INDIA	1884		24	0.8%	1.6%	9.9%	170		25	0.8%	8.2%	17.9%
AJANTA	1796		25	0.8%	10.7%	6.1%	179		24	0.9%	14.0%	7.8%
LA RENON	1759		26	0.8%	12.9%	2.9%	146		27	0.7%	8.4%	2.7%
HIMALAYA	1703		27	0.7%	5.1%	-8.3%	154		26	0.8%	8.3%	-9.7%
PROCTER AND GAMBLE	1469		28	0.6%	12.7%	2.9%	118		30	0.6%	4.0%	-2.8%
CORONA	1453		29	0.6%	13.9%	7.2%	143		28	0.7%	15.8%	8.3%
INDOCO	1330		30	0.6%	10.3%	3.2%	125		29	0.6%	5.4%	-4.7%
FRANCO	1305		31	0.6%	1.3%	4.2%	116		31	0.6%	5.2%	6.0%
CADILA	1288		32	0.6%	-4.0%	-16.4%	107		37	0.5%	-8.9%	-20.9%
BAYER	1286		33	0.6%	13.4%	-7.6%	114		32	0.6%	13.4%	-19.0%
SYSTOPIC	1189		34	0.5%	8.9%	4.4%	107		36	0.5%	7.3%	4.0%
BLUE CROSS	1170		35	0.5%	-0.5%	-4.1%	109		34	0.5%	5.7%	1.6%
HETERO	1163		36	0.5%	2.7%	-6.2%	109		33	0.5%	6.4%	-7.4%
NUTRICIA	1119		37	0.5%	20.4%	13.9%	104		38	0.5%	20.1%	8.4%
HEGDE & HEGDE	1095		38	0.5%	8.6%	4.9%	89		40	0.4%	-2.2%	-4.3%
FOURRTS	1057		39	0.5%	5.6%	5.4%	92		39	0.4%	7.6%	11.5%
MEDLEY	1033		40	0.4%	1.2%	-5.8%	108		35	0.5%	3.8%	-6.3%

Source: BOBCAPS Research, Pharmarack

### GLP market in India witnessing good demand

In India, Liraglutide went off patent and many companies entered the market. Pen fill Semaglutide will likely go off patent in Mar'26 and Wegovy is launched ahead of that. The innovator has already launched Oral Semaglutide that is witnessing good demand. Many companies are expected to launch Pen fill Semaglutide post patent expiry, either on their own or through partner in the first wave. Companies like Dr. Reddy's and Eris are likely to launch Semaglutide on their own, whereas Lupin/Cipla are expected to launch through partner.

**Fig 9 – GLP brands in India**

Molecules	Company	Brands	Price (rs)	dosage	Type	Indication	Patent Expiry
Liraglutide	Novo Nordisk	Victoza	5234	6ml	Injection	Type 2 diabetes	Nov-24
	Eris	Erly	2000	3ml	Injection	Type 2 diabetes	
	Eris	Lyrato	2000	6ml	r-DNA injection	Type 2 diabetes	
	Glenmark	Lirafit	2032	3 ml	Biosimilar	Type 2 diabetes	
Semaglutide	Novo Nordisk	Saxenda	5599	6ml	Injection	Weight loss	Mar-26
	Novo Nordisk	Rybelsus	2853	3 mg	Tablets	weight loss and type 2 diabetes	
	Novo Nordisk	Wegovy	4336	0.25,0.5,1mg	Injection	weight loss and type 2 diabetes	
Tirzepatide	Eli Lilly	Mounjaro	5000	0.5 ml	Injection	Type 2 diabetes	2036
	Eli Lilly	Zepbound	5000	0.5 ml	Injection	Weight loss	
	Ziska Pharma	Tizaro	4000	0.5 ml	Injection	weight loss and type 2 diabetes	
Dulaglutide	Eli Lilly	Trulicity	4900	0.5 ml	Injection	Type 2 diabetes	Sep-39
	Lupin	Aplavant	4900	0.5 ml	r-DNA injection	Type 2 diabetes	

Source: , BOBCAPS Research, Pharmarack

**Fig 10 – GLP-1 Molecule size in India**

SUBGROUP	SUBGROUP LAUNCH DATE	MAT VAL RS CR				
		Jul-21	Jul-22	Jul-23	Jul-24	Jul-25
<b>GLP 1 AGONISTS</b>		<b>89</b>	<b>159</b>	<b>288</b>	<b>476</b>	<b>606</b>
SEMAGLUTIDE	Jan-22	0	34	155	332	421
TIRZEPATIDE	Mar-25	0	0	0	0	98
DULAGLUTIDE	Mar-16	47	67	71	84	62
LIRAGLUTIDE	Jun-10	41	58	63	59	25
LIXISENATIDE	Apr-16	0	0	0	0	0
EXENATIDE	Oct-07	0	0	0	0	0


Source: , BOBCAPS Research, Pharmarack

**Fig 11 – GLP-1 brand size in India**

BRAND	MTH VAL RS CR				
	MAR-25	APR-25	MAY-25	JUN-25	JUL-25
SEMAGLUTIDE	29	34	32	31	38
RYBELSUS	29	34	32	28	31
WEGOVY	0	0	0	3	7
TIRZEPATIDE	3	8	13	26	47
MOUNJARO	3	8	13	26	47

Source: , BOBCAPS Research, Pharmarack

**Fig 12 – GLP market trend**



Source: BOBCAPS Research, Pharmarack


## Company-wise top 20 products data

**Fig 13 – Abbott's top 20 products monthly sales (Rs mn)**

BRAND	SUBGROUP NAME	SUPERGROUP	SUBGROUP TYPE NAME	SV JUN 2025	SV JUL 2025	MoM growth (%)
ABBOTT				10,872	12,020	11
MIXTARD	HUMAN PREMIX INSULIN   A10C41	ANTI DIABETIC	CHRONIC	637	740	16
UDILIV	URSODEOXYCHOLIC ACID   A5A219	GASTRO INTESTINAL	ACUTE	525	591	13
RYZODEG	INSULIN DEGLUDEC + INSULIN ASPART   A10C33	ANTI DIABETIC	CHRONIC	419	459	9
THYRONORM	LEVO-THYROXINE (SYNTHETIC)   H3A002	HORMONES	CHRONIC	504	539	7
RYBELSUS	SEMAGLUTIDE   A10S5	ANTI DIABETIC	CHRONIC	284	308	9
VERTIN	BETAHISTINE   N7C319	NEURO / CNS	SUB CHRONIC	313	359	15
NOVOMIX	BIPHASIC ASPART   A10C31	ANTI DIABETIC	CHRONIC	223	245	10
DUPHALAC	LACTULOSE   A6A149	GASTRO INTESTINAL	ACUTE	267	303	13
DUPHASTON	DYDROGESTERONE   G3A549	GYNAECOLOGICAL	SUB CHRONIC	233	250	7
STEMETIL	PROCHLORPERAZINE   A4A1129	GASTRO INTESTINAL	ACUTE	240	249	4
CREMAFFIN PLUS	LIQUID PARAFFIN + MILK OF MAGNESIA + SODIUM PICOSULPHATE   A6A1019	GASTRO INTESTINAL	ACUTE	187	215	15
ACTRAPID	REGULAR HUMAN INSULIN   A10C71	ANTI DIABETIC	CHRONIC	178	207	16
ACITROM	ACENOCOUMAROL   B1A4	CARDIAC	CHRONIC	177	192	8
NOVORAPID	REGULAR ASPART   A10C13	ANTI DIABETIC	CHRONIC	128	146	14
TRESIBA	DEGLUDEC   A10C51	ANTI DIABETIC	CHRONIC	129	152	18
DIGENE	ALUMINIUM + MAGNESIUM + SIMETHICONE   A2A1210	GASTRO INTESTINAL	ACUTE	139	146	5
LIMCEE	PLAIN VITAMIN C   A11G12	VITAMINS / MINERALS / NUTRIENTS	SUB CHRONIC	146	170	16
KENACORT	TRIAMCINOLONE   D7A1016	DERMA	ACUTE	131	139	6
LMWX	ENOXAPARIN   B1B24	CARDIAC	CHRONIC	107	144	34
SIMILAC	INFANT FORMULAS   V6C001	VITAMINS / MINERALS / NUTRIENTS	SUB CHRONIC	116	119	2

Source: BOBCAPS Research, Pharमारack

**Fig 14 – Abbott's monthly sales data**




Source: BOBCAPS Research, Pharमारack

**Fig 15 – Alkem's top 20 products monthly sales (Rs mn)**

BRAND	SUBGROUP NAME	SUPERGROUP	SUBGROUP TYPE NAME	JUN 2025	JUL 2025	MoM growth (%)
ALKEM				7,981	8,380	5
PAN	PANTOPRAZOLE   A2B219	GASTRO INTESTINAL	SUB CHRONIC	709	677	(4)
PAN D	DOMPERIDONE + PANTOPRAZOLE   A2B1769	GASTRO INTESTINAL	ACUTE	594	563	(5)
CLAVAM	AMOXYCILLIN + CLAVULANIC ACID   J1C801	ANTI-INFECTIVES	ACUTE	509	541	6
TAXIM O	CEFIXIME   J1D234	ANTI-INFECTIVES	ACUTE	295	324	10
A TO Z NS	MULTIVITAMINS + MINERALS   A11A023	VITAMINS / MINERALS / NUTRIENTS	SUB CHRONIC	313	330	5
PIPZO	PIPERACILLIN + TAZOBACTAM   J1H003	ANTI-INFECTIVES	ACUTE	227	222	(2)
XONE	CEFTRIAXONE   J1D2311	ANTI-INFECTIVES	ACUTE	190	184	(3)
UPRISE D3	CHOLECALCIFEROL   A11C35	VITAMINS / MINERALS / NUTRIENTS	SUB CHRONIC	194	207	7
ONDEM	ONDANSETRON   A4A159	GASTRO INTESTINAL	ACUTE	164	164	0
SUMO L	PARACETAMOL   N2B406	PAIN / ANALGESICS	ACUTE	153	170	11
TAXIM	CEFOTAXIME   J1D236	ANTI-INFECTIVES	ACUTE	144	153	6
SUMO	NIMESULIDE + PARACETAMOL   M1A2251	PAIN / ANALGESICS	ACUTE	114	125	10
XONE XP	CEFTRIAXONE + TAZOBACTAM   J1D2211	ANTI-INFECTIVES	ACUTE	111	126	13
MEROSURE	MEROPENEM   J1P206	ANTI-INFECTIVES	ACUTE	101	109	8
GEMCAL	CALCITRIOL + CALCIUM + ZINC   A11A711	VITAMINS / MINERALS / NUTRIENTS	SUB CHRONIC	108	115	7
SWICH	CEFPODOXIME   J1D237	ANTI-INFECTIVES	ACUTE	72	79	9
ZOCEF	CEFUROXIME   J1D242	ANTI-INFECTIVES	ACUTE	83	90	8
NEW A TO Z GOLD	ANTI-OXIDANTS + MINERALS + VITAMINS   V3X5011	VITAMINS / MINERALS / NUTRIENTS	ACUTE	80	79	(1)
GLUCORYL-MV	VOGLIBOSE + METFORMIN + GLIMEPIRIDE   A10J33	ANTI DIABETIC	CHRONIC	70	71	2
CHERI	ELEMENTAL IRON + FOLIC ACID + VITAMIN B12   B3A003	BLOOD RELATED	SUB CHRONIC	64	70	9

Source: BOBCAPS Research, Pharmarack

**Fig 16 – Alkem's monthly sales data**



Source: BOBCAPS Research, Pharmarack

**Fig 17 – AstraZeneca top 20 products monthly sales data (Rs mn)**

BRAND	SUBGROUP NAME	SUPERGROUP	SUBGROUP TYPENAME	JUN 2025	JUL 2025	MoM growth (%)
ASTRAZENECA				821	838	2
BRILINTA	TICAGRELOR   B1C81	CARDIAC	CHRONIC	353	347	(2)
ZOLADEX	GOSERELIN   L2A302	ANTI-NEOPLASTICS	ACUTE	92	100	9
FORXIGA	DAPAGLIFLOZIN   A10P36	ANTI DIABETIC	CHRONIC	82	88	8
CRESTOR	ROSUVASTATIN   C10A15	CARDIAC	CHRONIC	81	83	3
SELOKEN	METOPROLOL   C7A29	CARDIAC	CHRONIC	50	49	(2)
ARIMIDEX	ANASTROZOLE   L2B32	ANTI-NEOPLASTICS	CHRONIC	50	58	15
BETALOC	METOPROLOL   C7A29	CARDIAC	CHRONIC	43	41	(6)
XIGDUO	DAPAGLIFLOZIN + METFORMIN   A10P32	ANTI DIABETIC	CHRONIC	32	30	(6)
TAGRISSO	OSIMERTINIB   L1H22	ANTI-NEOPLASTICS	CHRONIC	4	5	22
IMDUR	ISOSORBIDE-5-MONONITRATE   C1E17	CARDIAC	CHRONIC	6	4	(38)
QTERN	DAPAGLIFLOZIN + SAXAGLIPTIN   A10P51	ANTI DIABETIC	CHRONIC	7	7	6
KOMBIGLYZE	SAXAGLIPTIN + METFORMIN   A10N12	ANTI DIABETIC	CHRONIC	1	1	(53)
IMFINZI	DURVALUMAB   L1X107	ANTI-NEOPLASTICS	CHRONIC	8	3	58
ONGLYZA	SAXAGLIPTIN   A10N5	ANTI DIABETIC	CHRONIC	8	7	(15)
ENHERTU	TRASTUZUMAB   L1G32	ANTI-NEOPLASTICS	CHRONIC	0	0	50
CASODEX	BICALUTAMIDE   L2B41	ANTI-NEOPLASTICS	CHRONIC	3	4	59
FASLODEX	FULVESTRANT   L2B91	ANTI-NEOPLASTICS	ACUTE	1	2	36
LYNPARZA	OLAPARIB   L1L1	ANTI-NEOPLASTICS	CHRONIC	0	0	NA
XYLOCARD	LIDOCAINE   N1C103	PAIN / ANALGESICS	ACUTE	0	0	(66)
DEFLOR	DEFLAZACORT   H2A006	HORMONES	SUB CHRONIC	0	0	99

Source: BOBCAPS Research, Pharmarack




**Fig 18 – Cipla top 20 products monthly sales data (Rs mn)**

BRAND	SUBGROUP NAME	SUPERGROUP	SUBGROUP TYPE NAME	SV JUN 2025	SV JUL 2025	MoM growth (%)
CIPLA				8,803	9,058	3
FORACORT	FORMOTEROL + BUDESONIDE   R3A164	RESPIRATORY	CHRONIC	532	528	-1
DUOLIN	LEVOSALBUTAMOL + IPRATROPIUM   R3A242	RESPIRATORY	CHRONIC	291	326	12
BUDECORT	BUDESONIDE   R3A281	RESPIRATORY	CHRONIC	210	224	7
SEROFLO	SALMETEROL + FLUTICASONE   R3A101	RESPIRATORY	CHRONIC	217	231	7
DYTOR	TORSEMIDE   C3A711	CARDIAC	CHRONIC	230	229	0
MONTAIR LC	MONTELUKAST + LEVOCETIRIZINE   R3J906	RESPIRATORY	ACUTE	184	179	-2
ASTHALIN	SALBUTAMOL   R3A402	RESPIRATORY	CHRONIC	151	161	7
IBUGESIC PLUS	IBUPROFEN + PARACETAMOL   M1A220	PAIN / ANALGESICS	ACUTE	192	185	-4
URIMAX D	TAMSULOSIN + DUTASTERIDE   G4C404	UROLOGY	SUB CHRONIC	148	147	-1
LEVOLIN	LEVOSALBUTAMOL   R3A401	RESPIRATORY	CHRONIC	94	102	9
AZEE	AZITHROMYCIN   J1F001	ANTI-INFECTIVES	ACUTE	111	118	6
AEROCORT	LEVOSALBUTAMOL + BECLOMETHASONE   R3A251	RESPIRATORY	CHRONIC	123	132	7
URIMAX	TAMSULOSIN   G4C203	UROLOGY	SUB CHRONIC	143	141	-1
DYTOR PLUS	SPIRONOLACTONE + TORSEMIDE   C3A143	CARDIAC	CHRONIC	132	126	-4
GALVUS MET	VILDAGLIPTIN + METFORMIN   A10N15	ANTI DIABETIC	CHRONIC	109	112	2
MUCINAC	ACETYLCYSTEINE   R5C201	RESPIRATORY	CHRONIC	87	86	-2
EMESET	ONDANSETRON   A4A159	GASTRO INTESTINAL	ACUTE	110	107	-3
ADVENT	AMOXYCILLIN + CLAVULANIC ACID   J1C801	ANTI-INFECTIVES	ACUTE	60	69	16
ELORES	CEFTRIAXONE + SULBACTAM + DISODIUM EDETATE   J1D2212	ANTI-INFECTIVES	ACUTE	97	95	-2
METOLAR	METOPROLOL   C7A29	CARDIAC	CHRONIC	71	74	5

Source: BOBCAPS Research, Pharmarack

**Fig 19 – Cipla's monthly sales data**




Source: BOBCAPS Research, Pharmarack

**Fig 20 – Dr.Reddy's top 20 products monthly sales data (Rs mn)**

BRAND	SUBGROUP NAME	SUPERGROUP	SUBGROUP TYPE NAME	JUN 2025	JUL 2025	MoM growth (%)
DR. REDDYS				5,794	6,355	10
ECONORM	SACCHAROMYCES BOULARDII   A7F2109	GASTRO INTESTINAL	ACUTE	233	247	6
KETOROL	KETOROLAC   M1A313	PAIN / ANALGESICS	ACUTE	183	191	4
OMEZ	OMEPRAZOLE   A2B279	GASTRO INTESTINAL	SUB CHRONIC	167	171	2
ATARAX	HYDROXYZINE   D11A61	DERMA	ACUTE	148	185	25
MINTOP	MINOXIDIL   D11A1760	DERMA	CHRONIC	129	150	16
OMEZ D PLUS	DOMPERIDONE + ESOMEPRAZOLE   A2B1729	GASTRO INTESTINAL	ACUTE	131	95	(27)
VOVERAN	DICLOFENAC   M1A308	PAIN / ANALGESICS	ACUTE	112	115	3
HEXAXIM	COMBINATIONS WITH TETANUS COMPONENT   J7B101	VACCINES	ACUTE	105	115	10
CIDMUS	SACUBITRIL + VALSARTAN   C10A121	CARDIAC	CHRONIC	110	117	6
DOXT SL	DOXYCYCLINE + LACTOBACILLUS   J1A302	ANTI-INFECTIVES	ACUTE	91	103	13
MENACTRA	MENINGOCOCCAL VACCINES, ALL TYPES   J7D201	VACCINES	ACUTE	101	121	20
RAZO D	DOMPERIDONE + RABEPRAZOLE   A2B1779	GASTRO INTESTINAL	ACUTE	101	104	3
VENUSIA MAX	EMOLLIENTS   D2A058	DERMA	SUB CHRONIC	83	101	22
VANTEJ	CALCIUM SODIUM PHOSPHOSILICATE + SODIUM LAURYL SULPHATE + POTASSIUM ACESULFAME   A1A100	STOMATOLOGICALS	ACUTE	101	108	7
ZEDEX	BROMHEXINE + DEXTROMETHORPHAN + AMMONIUM CHLORIDE   R5D203	RESPIRATORY	ACUTE	59	66	13
STAMLO	AMLODIPINE   C8A1	CARDIAC	CHRONIC	87	94	8
BRO ZEDEX	GUAIFENESIN + TERBUTALINE + BROMHEXINE   R3A602	RESPIRATORY	ACUTE	55	66	20
NISE	NIMESULIDE   M1A317	PAIN / ANALGESICS	ACUTE	73	79	7
CLAMP	AMOXYCILLIN + CLAVULANIC ACID   J1C801	ANTI-INFECTIVES	ACUTE	47	67	41
RESWAS	CHLORPHENIRAMINE + LEVODROPROPIZINE   R6A165	RESPIRATORY	ACUTE	49	60	21

Source: BOBCAPS Research, Pharमारack

**Fig 21 – Dr.Reddy's monthly sales**



Source: BOBCAPS Research, Pharमारack

**Fig 22 – Eli Lilly top 20 products monthly sales data (Rs mn)**

BRAND	SUBGROUP NAME	SUPERGROUP	SUBGROUP TYPE NAME	JUN 2025	JUL 2025	MoM growth (%)
ELI LILLY				406	616	52
MOUNJARO	TIRZEPATIDE   A10S6	ANTI DIABETIC	ACUTE	263	474	80
RAMIVEN	ABEMACICLIB   L1H52	ANTI-NEOPLASTICS	CHRONIC	89	101	14
CYRAMZA	RAMUCIRUMAB   L1G21	ANTI-NEOPLASTICS	CHRONIC	26	17	(36)
OLUMIANT	BARICITINIB   L4X41	ANTI-NEOPLASTICS	CHRONIC	18	17	(2)
ALIMTA	PEMETREXED   L1B51	ANTI-NEOPLASTICS	CHRONIC	4	3	(20)
HUMAN INSULIN	HUMAN PREMIX INSULIN   A10C41	ANTI DIABETIC	CHRONIC	4	2	(43)
GEMCITE	GEMCITABINE   L1B81	ANTI-NEOPLASTICS	CHRONIC	2	1	(6)
FORTEO	TERIPARATIDE   H4E001	HORMONES	SUB CHRONIC	0	0	0
BD	INSULIN DEVICES   A10E1	ANTI DIABETIC	CHRONIC	0	0	(23)
DOLCOFLEX	UNCLASSIFIED MOLECULES   U1A1	OTHERS	-	0	0	NA!

Source: BOBCAPS Research, Pharमारack

**Fig 23 – Top 20 brands data of the IPM**

CORPORATE	BRANDS	MAT Jul'25				MTH Jul'25					
		SALES	VAL	RANK	VAL GR%	UNIT GR%	SALES	VAL	RANK	VAL GR%	UNIT GR%
GSK	AUGMENTIN	828		1	4.1%	2.4%	80		1	10.5%	10.3%
USV	GLYCOMET GP	821		2	4.3%	1.0%	71		3	10.2%	2.7%
ALKEM*	PAN	788		3	8.8%	2.3%	68		4	6.5%	-0.9%
ABBOTT*	MIXTARD	775		4	2.2%	4.7%	74		2	10.3%	14.6%
HIMALAYA	LIV.52	767		5	12.6%	-3.8%	68		5	22.3%	0.4%
CIPLA	FORACORT	734		6	2.6%	1.9%	53		12	1.5%	-1.6%
ALKEM*	PAN D	672		7	15.1%	4.8%	56		8	3.3%	-6.1%
ALKEM*	CLAVAM	670		8	8.8%	0.6%	54		10	4.6%	-0.3%
ARISTO	MONOCEF	654		9	2.5%	2.0%	54		9	2.6%	0.6%
ABBOTT*	UDILIV	648		10	11.7%	0.6%	59		6	8.4%	-2.3%
IPCA	ZERODOL SP	648		11	5.8%	-1.2%	59		7	5.2%	-1.5%
ABBOTT*	RYZODEG	593		12	23.7%	23.6%	46		18	-8.4%	-7.2%
ABBOTT*	THYRONORM	570		13	15.8%	14.9%	54		11	16.2%	13.7%
WIN-MEDICARE	BETADINE	557		14	0.6%	-2.8%	49		14	0.4%	-4.9%
MANKIND*	MANFORCE	516		15	8.5%	8.6%	45		19	2.5%	1.5%
GLENMARK	TELMA	512		16	8.4%	8.1%	48		15	14.9%	16.4%
JB CHEMICALS	CILACAR	503		17	13.0%	4.1%	52		13	21.8%	13.1%
FDC	ELECTRAL	498		18	8.3%	13.8%	42		23	17.3%	7.3%
JANSSEN	ULTRACET	486		19	-0.6%	-8.8%	46		17	4.5%	-4.3%
CIPLA	DUOLIN	484		20	0.7%	-6.0%	33		33	1.5%	-4.0%

Source: BOBCAPS Research, Pharमारack

**Fig 24 – Next 20 brands data of IPM**

CORPORATE	BRANDS	MAT Jul'25				MTH Jul'25					
		SALES	VAL	RANK	VAL GR%	UNIT GR%	SALES	VAL	RANK	VAL GR%	UNIT GR%
USV	ECOSPRIN AV	469		21	14.0%	6.4%	43		22	20.6%	6.5%
FRANCO	DEXORANGE	468		22	-0.5%	-8.3%	44		20	-1.4%	-10.5%
SUN*	LEVIPIL	461		23	3.6%	2.1%	41		24	10.0%	6.2%
SANOFI INDIA	LANTUS	434		24	0.2%	-0.9%	43		21	16.6%	16.1%
SUN*	ROSUVAS	424		25	3.3%	-3.3%	36		28	-9.3%	-14.1%
GSK	CALPOL	423		26	6.3%	10.6%	34		31	-1.9%	0.3%
ARISTO	PANTOP	421		27	4.8%	4.4%	38		26	3.9%	1.5%
CIPLA	BUDECORT	417		28	-3.6%	-3.4%	22		85	-4.7%	-7.0%
ABBOTT*	RYBELSUS	411		29	23.7%	23.2%	31		42	4.9%	4.0%
APEX	ZINCOVIT	400		30	6.9%	0.2%	34		30	5.4%	0.6%
MICRO	DOLO	383		31	-8.3%	-9.6%	31		40	-17.5%	-18.9%
ARISTO	MIKACIN	374		32	-4.2%	-6.8%	31		38	-8.8%	-14.7%
CADILA	ACILOC	370		33	-13.9%	-20.3%	32		35	-16.3%	-25.7%
ASTRAZENECA	BRILINTA	364		34	14.9%	5.5%	35		29	30.0%	20.2%
ABBOTT*	VERTIN	363		35	9.6%	-2.5%	36		27	27.0%	12.8%
ABBOTT*	NOVOMIX	355		36	-1.3%	-9.4%	25		68	-17.7%	-19.4%
GSK	T BACT	354		37	8.2%	8.6%	41		25	9.0%	6.7%
LUPIN	GLUCONORM-G	354		38	7.5%	-0.7%	31		39	0.6%	-7.5%
EMCURE*	ZOSTUM	352		39	20.8%	11.9%	31		37	13.5%	9.7%
INTAS	LEVERA	349		40	13.1%	10.7%	30		48	13.2%	8.9%


Source: BOBCAPS Research, Pharमारack

**Fig 25 – Eris top 20 products monthly sales data (Rs mn)**

BRAND	SUBGROUP NAME	SUPERGROUP	SUBGROUP TYPE NAME	JUN 2025	JUL 2025	MoM growth (%)
ERIS LS				2,521	2,668	6
GLIMISAVE MV	VOGLIBOSE + METFORMIN + GLIMEPIRIDE   A10J33	ANTI DIABETIC	CHRONIC	84	90	8
GLIMISAVE M	GLIMEPIRIDE + METFORMIN   A10J23	ANTI DIABETIC	CHRONIC	63	65	4
BASALOG	GLARGINE   A10C53	ANTI DIABETIC	CHRONIC	69	63	(8)
INSUGEN	HUMAN PREMIX INSULIN   A10C41	ANTI DIABETIC	CHRONIC	62	62	0
RENERVE PLUS	ALA + CHROMIUM + FOLIC ACID + INOSITOL + METHYLCOBALAMIN + SELENO METHIONINE + ZINC MONOMETHIONINE   A11F190	VITAMINS / MINERALS / NUTRIENTS	SUB CHRONIC	67	69	4
RENERVE PLUS	METHYLCOBALAMIN + NIACINAMIDE + PYRIDOXINE   A11L3	VITAMINS / MINERALS / NUTRIENTS	ACUTE	48	49	3
CYBLEX MV	VOGLIBOSE + METFORMIN + GLICLAZIDE   A10J31	ANTI DIABETIC	CHRONIC	42	45	7
REMYLIN D	ALA + CHOLECALCIFEROL + FOLIC ACID + METHYLCOBALAMIN + PYRIDOXINE   A11F036	VITAMINS / MINERALS / NUTRIENTS	SUB CHRONIC	36	41	12
PSORID	CYCLOSPORIN   L4X11	ANTI-NEOPLASTICS	SUB CHRONIC	28	35	26
PROLOP	PARACETAMOL   N2B406	PAIN / ANALGESICS	ACUTE	17	22	29
BIOPIPER TZ	PIPERACILLIN + TAZOBACTAM   J1H003	ANTI-INFECTIVES	ACUTE	27	22	(20)
XSULIN	HUMAN PREMIX INSULIN   A10C41	ANTI DIABETIC	CHRONIC	41	44	6
ERITEL CH	TELMISARTAN + CHLORTHALIDONE   C9D128	CARDIAC	CHRONIC	23	24	4
NEFCM	FERRIC CARBOXYMALTOSE COMPLEX   B3A302	BLOOD RELATED	ACUTE	33	36	8
ERITEL LN	CILNIDIPINE + TELMISARTAN   C9D311	CARDIAC	CHRONIC	25	27	8
ZOMELIS MET	VILDAGLIPTIN + METFORMIN   A10N15	ANTI DIABETIC	CHRONIC	24	29	21
INSUGEN R	REGULAR HUMAN INSULIN   A10C71	ANTI DIABETIC	CHRONIC	31	33	6
COSVATE GM	CLOBETASOL + GENTAMICIN + MICONAZOLE   D7B3012	DERMA	SUB CHRONIC	27	26	(4)
PROTOTAL WHEY	PROTEIN SUPPLEMENTS   V6B104	VITAMINS / MINERALS / NUTRIENTS	SUB CHRONIC	36	38	4
TENDIA M	TENELIGLIPTIN + METFORMIN   A10N14	ANTI DIABETIC	CHRONIC	23	25	6

Source: BOBCAPS Research, Pharमारack

**Fig 26 – Eris Monthly sales data**




Source: BOBCAPS Research, Pharमारack

**Fig 27 – GSK top 20 products monthly sales data (Rs mn)**

BRAND	SUBGROUP NAME	SUPERGROUP	SUBGROUP TYPE NAME	JUN 2025	JUL 2025	MoM growth (%)
GSK				3,611	4,341	20
AUGMENTIN	AMOXYCILLIN + CLAVULANIC ACID   J1C801	ANTI-INFECTIVES	ACUTE	524	797	52
CALPOL	PARACETAMOL   N2B406	PAIN / ANALGESICS	ACUTE	302	343	13
T BACT	MUPIROCIN   D6A907	DERMA	SUB CHRONIC	264	405	54
BETNOVATE N	BETAMETHASONE + NEOMYCIN   D7B1008	DERMA	SUB CHRONIC	259	222	(14)
BETNOVATE C	BETAMETHASONE + CLIOQUINOL   D7B103	DERMA	CHRONIC	262	259	(1)
ELTROXIN	LEVO-THYROXINE (SYNTHETIC)   H3A002	HORMONES	CHRONIC	197	229	16
CEFTUM	CEFUROXIME   J1D242	ANTI-INFECTIVES	ACUTE	138	141	2
NEOSPORIN	BACITRACIN + NEOMYCIN + POLYMYXIN B   D6A81	DERMA	ACUTE	143	176	23
CCM	CCM - PLAIN / COMBINATIONS   A11A738	VITAMINS / MINERALS / NUTRIENTS	SUB CHRONIC	119	145	22
BETNESOL	BETAMETHASONE   H2A005	HORMONES	ACUTE	89	103	16
INFANRIX HEXA	DIPHTHERIA TOXOID + PERTUSSIS TOXOID + TETANUS TOXOID + POLIOMYELITIS VIRUS TYPE 1,2,3   J7B102	VACCINES	ACUTE	73	95	30
COBADEX CZS	MULTIVITAMINS + MINERALS   A11A023	VITAMINS / MINERALS / NUTRIENTS	SUB CHRONIC	69	73	6
OTRIVIN OXY	OXYMETAZOLINE   R1A191	RESPIRATORY	ACUTE	48	55	14
PHEXIN	CEFALEXIN   J1D102	ANTI-INFECTIVES	ACUTE	54	70	30
BETNOVATE GM	BETAMETHASONE + GENTAMICIN + MICONAZOLE   D7B309	DERMA	SUB CHRONIC	44	58	32
TENOVATE	CLOBETASOL   D7A104	DERMA	ACUTE	51	55	9
BOOSTRIX	DIPHTHERIA TOXOID + TETANUS TOXOID + PERTUSSIS TOXOID   J7B104	VACCINES	ACUTE	63	72	14
SUPACEF	CEFUROXIME   J1D242	ANTI-INFECTIVES	ACUTE	41	48	16
CROCIN	PARACETAMOL   N2B406	PAIN / ANALGESICS	ACUTE	31	35	14
VARILRIX	VARICELLA VACCINE   J7E201	VACCINES	ACUTE	46	60	30

Source: BOBCAPS Research, Pharमारack

**Fig 28 – GSK Monthly sales data**




Source: BOBCAPS Research, Pharमारack

**Fig 29 – IPCA top 20 products monthly sales data (Rs mn)**

BRAND	SUBGROUP NAME	SUPERGROUP	SUBGROUP TYPE NAME	JUN 2025	JUL 2025	MoM growth (%)
IPCA				3,669	4,004	9
ZERODOL SP	ACECLOFENAC + PARACETAMOL + SERRATIOPEPTIDASE   M1A245	PAIN / ANALGESICS	ACUTE	547	590	8
ZERODOL P	ACECLOFENAC + PARACETAMOL   M1A2221	PAIN / ANALGESICS	ACUTE	232	230	(1)
HCQS	HYDROXYCHLOROQUINE   P1D112	ANTI MALARIALS	CHRONIC	164	171	4
FOLITRAX	METHOTREXATE   L1B41	ANTI-NEOPLASTICS	CHRONIC	132	146	11
ZERODOL TH	THIOLCHOLCHICOSIDE + ACECLOFENAC   M3B317	PAIN / ANALGESICS	ACUTE	112	123	10
CTD T	TELMISARTAN + CHLORTHALIDONE   C9D128	CARDIAC	CHRONIC	86	101	18
LACTAGARD	CEFOPERAZONE + SULBACTAM   J1D223	ANTI-INFECTIVES	ACUTE	74	91	24
SOLVIN COLD	CHLORPHENIRAMINE + PHENYLEPHRINE + PARACETAMOL   R5A509	RESPIRATORY	ACUTE	56	63	12
PACIMOL	PARACETAMOL   N2B406	PAIN / ANALGESICS	ACUTE	60	71	18
CTD	CHLORTHALIDONE   C3A63	CARDIAC	CHRONIC	62	66	5
LARIAGO	CHLOROQUINE   P1D111	ANTI MALARIALS	ACUTE	53	64	21
SAAZ	SULFASALAZINE   A7E149	GASTRO INTESTINAL	CHRONIC	57	61	6
ZERODOL MR	ACECLOFENAC + TIZANIDINE   M3B304	PAIN / ANALGESICS	ACUTE	59	64	8
PARI	PAROXETINE   N6B669	NEURO / CNS	CHRONIC	52	59	12
PACIMOL MF	MEFENAMIC ACID + PARACETAMOL   M1A223	PAIN / ANALGESICS	ACUTE	47	60	28
GLYCINORM M	GLICLAZIDE + METFORMIN   A10J22	ANTI DIABETIC	CHRONIC	48	51	6
AZIBACT	AZITHROMYCIN   J1F001	ANTI-INFECTIVES	ACUTE	38	46	19
RAPICLAV	AMOXYCILLIN + CLAVULANIC ACID   J1C801	ANTI-INFECTIVES	ACUTE	37	48	27
LEFNO	LEFLUNOMIDE   M5X307	PAIN / ANALGESICS	SUB CHRONIC	43	46	9
ZERODOL	ACECLOFENAC   M1A304	PAIN / ANALGESICS	ACUTE	42	43	4

Source: BOBCAPS Research, Pharमारack

**Fig 30 – IPCA monthly sales data**




Source: BOBCAPS Research, Pharमारack

**Fig 31 – Lupin top 20 products monthly sales data (Rs mn)**

BRAND	SUBGROUP NAME	SUPERGROUP	SUBGROUP TYPE NAME	JUN 2025	JUL 2025	MoM growth (%)
LUPIN				6,523	7,228	11
GLUCONORM-G	GLIMEPIRIDE + METFORMIN   A10J23	ANTI DIABETIC	CHRONIC	298	310	4
BUDAMATE	FORMOTEROL + BUDESONIDE   R3A164	RESPIRATORY	CHRONIC	153	174	13
HUMINSULIN	HUMAN PREMIX INSULIN   A10C41	ANTI DIABETIC	CHRONIC	151	170	13
IVABRAD	IVABRADINE   C1D119	CARDIAC	CHRONIC	143	157	10
RABLET-D	DOMPERIDONE + RABEPRAZOLE   A2B1779	GASTRO INTESTINAL	ACUTE	102	115	13
TONACT	ATORVASTATIN   C10A16	CARDIAC	CHRONIC	104	112	8
SIGNOFLAM	ACECLOFENAC + PARACETAMOL + SERRATIOPEPTIDASE   M1A245	PAIN / ANALGESICS	ACUTE	77	91	18
CETIL	CEFUROXIME   J1D242	ANTI-INFECTIVES	ACUTE	72	84	16
NOVASTAT	ROSUVASTATIN   C10A15	CARDIAC	CHRONIC	74	88	18
NOVASTAT CV	ROSUVASTATIN + CLOPIDOGREL   B1C74	CARDIAC	CHRONIC	75	82	9
AJADUO	EMPAGLIFLOZIN + LINAGLIPTIN   A10P54	ANTI DIABETIC	CHRONIC	37	43	15
RCIFAX	RIFAXIMIN   A7A3119	GASTRO INTESTINAL	ACUTE	71	77	8
BEPLEX FORTE	VITAMIN B COMPLEX WITH VITAMIN C ONLY   A11E201	VITAMINS / MINERALS / NUTRIENTS	SUB CHRONIC	56	49	(12)
RABLET	RABEPRAZOLE   A2B299	GASTRO INTESTINAL	SUB CHRONIC	56	65	16
EPILIVE	LEVETIRACETAM   N3A929	NEURO / CNS	CHRONIC	59	63	8
ESIFLO	SALMETEROL + FLUTICASONE   R3A101	RESPIRATORY	CHRONIC	52	56	8
FAA-20	ELEMENTAL IRON + FOLIC ACID + VITAMIN B12 + ZINC   B3A005	BLOOD RELATED	SUB CHRONIC	60	70	17
FORMOFLO	FORMOTEROL + FLUTICASONE   R3A165	RESPIRATORY	CHRONIC	51	54	6
ONDERO	LINAGLIPTIN   A10N4	ANTI DIABETIC	CHRONIC	57	70	24
HUMINSULIN R	REGULAR HUMAN INSULIN   A10C71	ANTI DIABETIC	CHRONIC	54	62	14

Source: BOBCAPS Research, Pharmarack

**Fig 32 – Lupin's monthly sales data**




Source: BOBCAPS Research, Pharmarack

**Fig 33 – Mankind top 20 products monthly sales data (Rs mn)**

BRAND	SUBGROUP NAME	SUPERGROUP	SUBGROUP TYPE NAME	JUN 2025	JUL 2025	MoM growth (%)
MANKIND				11,484	11,978	4
MANFORCE	SILDENAFIL   G4E101	SEX STIMULANTS / REJUVENATORS	CHRONIC	456	451	(1)
MOXIKIND CV	AMOXYCILLIN + CLAVULANIC ACID   J1C801	ANTI-INFECTIVES	ACUTE	242	278	15
PREGA NEWS	PREGNANCY AND OVULATION TESTS   T2A1	OTHERS	ACUTE	264	250	(5)
AMLOKIND-AT	ATENOLOL + AMLODIPINE   C6B313	CARDIAC	CHRONIC	232	230	(1)
UNWANTED KIT	MIFEPRISTONE + MISOPROSTOL   G2A891	GYNAECOLOGICAL	ACUTE	238	222	(7)
CANDIFORCE	ITRACONAZOLE   J2A0013	ANTI-INFECTIVES	ACUTE	148	174	18
GUDCEF	CEFPODOXIME   J1D237	ANTI-INFECTIVES	ACUTE	144	154	7
DYDROBOON	DYDROGESTERONE   G3A549	GYNAECOLOGICAL	SUB CHRONIC	205	196	(4)
GLIMESTAR M	GLIMEPIRIDE + METFORMIN   A10J23	ANTI DIABETIC	CHRONIC	166	170	2
TELMIKIND AM	TELMISARTAN + AMLODIPINE   C9D312	CARDIAC	CHRONIC	156	164	6
PANTAKIND	PANTOPRAZOLE   A2B219	GASTRO INTESTINAL	SUB CHRONIC	175	194	11
TELMIKIND	TELMISARTAN   C91C6	CARDIAC	CHRONIC	135	140	4
LONOPIN	ENOXAPARIN   B1B24	CARDIAC	CHRONIC	147	152	3
NUROKIND LC	FOLIC ACID + L-CARNITINE + METHYLCOBALAMIN   A11F136	VITAMINS / MINERALS / NUTRIENTS	SUB CHRONIC	143	154	7
TELMIKIND H	TELMISARTAN + HYDROCHLORTHIAZIDE   C9D129	CARDIAC	CHRONIC	137	136	(1)
HUMOG HP	HUMAN MENOPAUSAL GONADOTROPHIN   G3G269	GYNAECOLOGICAL	SUB CHRONIC	171	182	6
VOMIKIND	ONDANSETRON   A4A159	GASTRO INTESTINAL	ACUTE	135	126	(7)
CEFAKIND	CEFUROXIME   J1D242	ANTI-INFECTIVES	ACUTE	103	113	10
ASTHAKIND DX	CHLORPHENIRAMINE + DEXTROMETHORPHAN + PHENYLEPHRINE   R5A187	RESPIRATORY	ACUTE	72	72	(1)
GUDCEF CV	CEFPODOXIME + CLAVULANIC ACID   J1D226	ANTI-INFECTIVES	ACUTE	80	88	10

Source: BOBCAPS Research, Pharmarac

**Fig 34 – Mankind's monthly sales data**



Source: BOBCAPS Research, Pharmarack




**Fig 35 – Pfizer top 20 products monthly sales data**

BRAND	SUBGROUP NAME	SUPERGROUP	SUBGROUP TYPE NAME	JUN 2025	JUL 2025	MoM growth (%)
PFIZER				2,328	2,771	19
BECOSULES	VITAMIN B COMPLEX WITH VITAMIN C ONLY   A11E201	VITAMINS / MINERALS / NUTRIENTS	SUB CHRONIC	216	247	14
COREX DX	CHLORPHENIRAMINE + DEXTROMETHORPHAN   R6A164	RESPIRATORY	ACUTE	192	207	8
MINIPRESS XL	PRAZOSIN   C2A29	CARDIAC	CHRONIC	152	191	26
MUCAINE	OXETACAINE + ALUMINIUM + MAGNESIUM   A2A549	GASTRO INTESTINAL	ACUTE	156	197	26
DOLONEX	PIROXICAM   M1A364	PAIN / ANALGESICS	ACUTE	99	124	25
GELUSIL MPS	ALUMINIUM + DIMETHICONE + MAGNESIUM   A2A289	GASTRO INTESTINAL	ACUTE	115	136	18
DALACIN C	CLINDAMYCIN   J1F301	ANTI-INFECTIVES	ACUTE	94	119	27
WYSOLONE	PREDNISOLONE   H2A008	HORMONES	ACUTE	94	112	18
ELIQUIS	APIXABAN   B1F1	CARDIAC	CHRONIC	72	89	24
FOLVITE	FOLIC ACID   B3A503	BLOOD RELATED	ACUTE	68	89	30
ZAVICEFTA	CEFTAZIDIME + AVIBACTAM   J1D227	ANTI-INFECTIVES	ACUTE	57	70	25
MERONEM	MEROPENEM   J1P206	ANTI-INFECTIVES	ACUTE	77	81	5
OVRL L	ETHINYLESTRADIOL + LEVONORGESTREL   G3F891	GYNAECOLOGICAL	SUB CHRONIC	52	61	19
SOLU MEDROL	METHYL PREDNISOLONE   H2A002	HORMONES	ACUTE	48	55	14
MAGNEX	CEFOPERAZONE + SULBACTAM   J1D223	ANTI-INFECTIVES	ACUTE	63	93	48
MEDROL	METHYL PREDNISOLONE   H2A002	HORMONES	ACUTE	42	45	8
AUTRIN	FERROUS FUMARATE + VITAMIN B12 + FOLIC ACID   B3A2018	BLOOD RELATED	ACUTE	41	46	10
PREVENAR 13	PNEUMONIA   J7D101	VACCINES	ACUTE	54	57	6
CITRALKA	DISODIUM HYDROGEN CITRATE   G4A303	UROLOGY	ACUTE	45	57	27
BECOSULES Z	VITAMIN B COMPLEX WITH ZINC   A11A025	VITAMINS / MINERALS / NUTRIENTS	ACUTE	28	35	23

Source: BOBCAPS Research, Pharमारack

**Fig 36 – Pfizer top product sales**




Source: BOBCAPS Research, Pharमारack

**Fig 37 – Sanofi India top 20 products monthly sales data (Rs mn)**

BRAND	SUBGROUP NAME	SUPERGROUP	SUBGROUP TYPE NAME	JUN 2025	JUL 2025	MoM growth (%)
SANOFI INDIA				1,497	1,697	13
LANTUS	GLARGINE   A10C53	ANTI DIABETIC	CHRONIC	372	432	16
ALLEGRA	FEXOFENADINE   R6A0122	RESPIRATORY	ACUTE	136	167	23
ENTEROGERMIN A	BACILLUS CLAUSII   A7F289	GASTRO INTESTINAL	ACUTE	200	215	8
COMBIFLAM	IBUPROFEN + PARACETAMOL   M1A220	PAIN / ANALGESICS	ACUTE	120	162	35
AVIL	PHENIRAMINE   R6A0133	RESPIRATORY	ACUTE	188	180	(5)
TOUJEO	GLARGINE   A10C53	ANTI DIABETIC	CHRONIC	90	98	9
DULCOFLEX	BISACODYL   A6A919	GASTRO INTESTINAL	ACUTE	79	94	20
APIDRA	GLULISINE   A10C11	ANTI DIABETIC	CHRONIC	58	67	15
ALLEGRA M	MONTELUKAST + FEXOFENADINE   R3J905	RESPIRATORY	ACUTE	38	45	19
BUSCOGAST	HYOSCINE   A2A509	GASTRO INTESTINAL	ACUTE	66	74	13
THYMOGLOBULIN	ANTITHYMOCYTE IMMUNOGLOBULINS   L4X71	ANTI-NEOPLASTICS	SUB CHRONIC	38	43	14
SOLIQUA SOLOSTAR	INSULIN GLARGINE + LIXISENATIDE   A10C92	ANTI DIABETIC	CHRONIC	16	17	7
ALLSTAR	INSULIN DEVICES   A10E1	ANTI DIABETIC	CHRONIC	12	14	14
DEPURA	CHOLECALCIFEROL   A11C35	VITAMINS / MINERALS / NUTRIENTS	SUB CHRONIC	18	24	30
TRENTAL	PENTOXIFYLLINE   B1C131	CARDIAC	CHRONIC	14	9	(38)
ALLEGRA	FLUTICASONE FUROATE   R3D106	RESPIRATORY	ACUTE	12	9	(22)
FESTAL N	PANCREATIN   A9C69	GASTRO INTESTINAL	SUB CHRONIC	9	10	9
BARALGAN NU	DICYCLOMINE + PARACETAMOL   A3A4139	GASTRO INTESTINAL	ACUTE	5	6	14
AMARYL MP	GLIMEPIRIDE + METFORMIN + PIOGLITAZONE   A10J39	ANTI DIABETIC	CHRONIC	2	1	(13)
CEREZYME	IMIGLUCERASE   A9D49	GASTRO INTESTINAL	ACUTE	4	4	2

Source: BOBCAPS Research, Pharmarack

**Fig 38 – Sanofi's monthly sales data**




Source: BOBCAPS Research, Pharmarack

**Fig 39 – Torrent Pharma top 20 products monthly sales data**

BRAND	SUBGROUP NAME	SUPERGROUP	SUBGROUP TYPE NAME	JUN 2025	JUL 2025	MoM growth (%)
TORRENT				6,832	7,624	12
CHYMORAL FORTE	CHYMOTRYPSIN + TRYPSIN   V3H002	PAIN / ANALGESICS	ACUTE	275	320	17
SHELCAL	CALCIUM + CHOLECALCIFEROL   A11A58	VITAMINS / MINERALS / NUTRIENTS	SUB CHRONIC	236	270	15
NEXPRO RD	DOMPERIDONE + ESOMEPRAZOLE   A2B1729	GASTRO INTESTINAL	ACUTE	232	261	13
NIKORAN	NICORANDIL   C8B111	CARDIAC	CHRONIC	194	214	11
SHELCAL XT	CALCIUM + CHOLECALCIFEROL + FOLIC ACID + METHYLCOBALAMIN + PYRIDOXINE   A11A720	VITAMINS / MINERALS / NUTRIENTS	SUB CHRONIC	159	173	9
NEBICARD	NEBIVOLOL   C7A43	CARDIAC	CHRONIC	140	138	(2)
TEDIBAR	EMOLLIENTS   D2A058	DERMA	SUB CHRONIC	115	124	8
NEXPRO	ESOMEPRAZOLE   A2B249	GASTRO INTESTINAL	SUB CHRONIC	111	129	16
VELOZ D	DOMPERIDONE + RABEPRAZOLE   A2B1779	GASTRO INTESTINAL	ACUTE	113	123	8
DILZEM	DILTIAZEM   C8A6	CARDIAC	CHRONIC	90	104	15
UNIENZYME	PAPAIN COMBINATIONS(WITHOUT ALPHA AMYLASE)   A9D69	GASTRO INTESTINAL	ACUTE	115	102	(11)
LACOSAM	LACOSAMIDE   N3A739	NEURO / CNS	SUB CHRONIC	85	102	20
SHELCAL HD	CALCIUM + CHOLECALCIFEROL   A11A58	VITAMINS / MINERALS / NUTRIENTS	SUB CHRONIC	88	99	12
AZULIX-MF	GLIMEPIRIDE + METFORMIN   A10J23	ANTI DIABETIC	CHRONIC	82	92	12
LAMITOR	LAMOTRIGINE   N3A749	NEURO / CNS	CHRONIC	88	84	(4)
LOSAR	LOSARTAN   C91C4	CARDIAC	CHRONIC	78	89	14
PRUVICT	PRUCALOPRIDE   A6B979	GASTRO INTESTINAL	ACUTE	71	80	13
ROZUCOR	ROSUVASTATIN   C10A15	CARDIAC	CHRONIC	73	82	14
LOSAR H	LOSARTAN + HYDROCHLORTHIAZIDE   C9D126	CARDIAC	CHRONIC	65	70	8
AMPOXIN	AMPICILLIN + CLOXACILLIN   J1C113	ANTI-INFECTIVES	ACUTE	65	76	17

Source: BOBCAPS Research, Pharmarac

**Fig 40 – Torrent's monthly sales data**



Source: BOBCAPS Research, Pharmarack

**Fig 41 – Abbott's in-licensed Novo Nordisk portfolio (Rs mn)**

CORPORATE	COMPANY	BRAND	MAT VAL JUL 24	MAT VAL JUL 25	YoY growth (%)
ABBOTT	NOVO NORDISK INDIA PVT LTD		28,162.6	30,560.3	9
ABBOTT	NOVO NORDISK INDIA PVT LTD	MIXTARD	7,579.7	7,745.0	2
ABBOTT	NOVO NORDISK INDIA PVT LTD	RYZODEG	4,792.2	5,927.4	24
ABBOTT	NOVO NORDISK INDIA PVT LTD	RYBELSUS	3,323.8	4,113.0	24
ABBOTT	NOVO NORDISK INDIA PVT LTD	NOVOMIX	3,597.0	3,549.6	(1)
ABBOTT	NOVO NORDISK INDIA PVT LTD	ACTRAPID	1,900.3	2,374.2	25
ABBOTT	NOVO NORDISK INDIA PVT LTD	NOVORAPID	1,792.0	1,888.1	5
ABBOTT	NOVO NORDISK INDIA PVT LTD	TRESIBA	1,811.5	1,877.2	4
ABBOTT	NOVO NORDISK INDIA PVT LTD	FIASP	994.0	1,177.7	18
ABBOTT	NOVO NORDISK INDIA PVT LTD	NOVOFINE	773.0	838.8	9
ABBOTT	NOVO NORDISK INDIA PVT LTD	INSULATARD	223.4	349.7	57
ABBOTT	NOVO NORDISK INDIA PVT LTD	NOVOPEN	150.4	278.9	85
ABBOTT	NOVO NORDISK INDIA PVT LTD	LEVEMIR	283.3	143.3	(49)
ABBOTT	NOVO NORDISK INDIA PVT LTD	WEGOVY	00.0	97.3	NA
ABBOTT	NOVO NORDISK INDIA PVT LTD	XULTOPHY	346.9	75.3	(78)
ABBOTT	NOVO NORDISK INDIA PVT LTD	NOVONORM	30.4	58.9	93
ABBOTT	NOVO NORDISK INDIA PVT LTD	HUMAN MONOTARD	33.3	50.7	52
ABBOTT	NOVO NORDISK INDIA PVT LTD	VICTOZA	524.7	13.0	(98)
ABBOTT	NOVO NORDISK INDIA PVT LTD	GLUCAGEN	00.6	1.1	72
ABBOTT	NOVO NORDISK INDIA PVT LTD	GLUCAGON	0.5	0.3	(27)
ABBOTT	NOVO NORDISK INDIA PVT LTD	INSULIN (NND)	0.5	0.3	(39)
ABBOTT	NOVO NORDISK INDIA PVT LTD	NOVO EIGHT	5.1	0.2	(95)
ABBOTT	NOVO NORDISK INDIA PVT LTD	INSULINE BOVINE	0.2	0.1	(24)
ABBOTT	NOVO NORDISK INDIA PVT LTD	INSULIN NPH	0.0	0.0	132
ABBOTT	NOVO NORDISK INDIA PVT LTD	GLOW	0.0	0.0	(65)
ABBOTT	NOVO NORDISK INDIA PVT LTD	HUMAN MONOTARD SC	0.0	0.0	NA
ABBOTT	NOVO NORDISK INDIA PVT LTD	NOVOSEVEN (EPTACCOG ALFA)	0.0	0.0	NA
ABBOTT	NOVO NORDISK INDIA PVT LTD	NORDITROPIN NORDILET	0.0	0.0	NA
ABBOTT	NOVO NORDISK INDIA PVT LTD	ACTRAPID SC.	0.0	0.0	NA
ABBOTT	NOVO NORDISK INDIA PVT LTD	INSULIN ZINC	0.0	0.0	NA

Source: BOBCAPS Research, Pharmanac

## Outlook on IPM

The IPM growth is expected to sustain at the current 7-9% for CY2025, driven by:

- 1- Price hike: NLEM price hike of 1.74% in April'25 was announced where companies largely have 12-15% of their domestic sales in NLEM, except Sanofi that has >40% of sales from NLE. However, companies can take price hike of 5-7% on products outside the NLEM.
- 2- New Product Launches: IPM growth from new product launches is stable at 2.5%. However, therapy-wise, Anti -Diabetic witnessed the highest growth at 6.3%, followed by Blood-related therapy (4.7%). New product growth for Diabetes therapy is expected to surge as Semaglutide gets LoE in the domestic market in Mar'26.

### Data of recent new product launches:

**Fig 42 – New product launches monthly sales data**

SUPER GROUP	BRAND	LAUNCH DATE	CORPORATE	JUN-25	JUL-25
<b>TOTAL</b>				<b>1,854.5</b>	<b>2,318.9</b>
<b>ANTI DIABETIC</b>					
ANTI DIABETIC	MOUNJARO	Mar-25	ELI LILLY	263.1	474.1
ANTI DIABETIC	LINAXA E	Mar-25	TORRENT	6.4	7.1
ANTI DIABETIC	EMPANORM L	Mar-25	ALKEM	7.3	7.2
ANTI DIABETIC	EMPAGLYDE L	Mar-25	MANKIND	2.3	2.5
ANTI DIABETIC	LINACIP E	Mar-25	CIPLA	1.7	2.2
ANTI DIABETIC	GLIPTOZA	Feb-25	ERIS LS	2.7	2.8
ANTI DIABETIC	LYRATO	Feb-25	ERIS LS	0.2	0.3
<b>GASTRO INTESTINAL</b>					
GASTRO INTESTINAL	VONCHAMP	Feb-25	ALKEM	1.4	1.4
GASTRO INTESTINAL	PROTOCHECK DSR	Apr-25	IPCA	2.3	2.5
GASTRO INTESTINAL	ELOBETRA	Mar-25	TORRENT	3.9	4.5
GASTRO INTESTINAL	REHEPTIN UD	May-25	MANKIND	1.7	2.8
<b>CARDIAC</b>					
CARDIAC	CILAHEART TM	Jun-25	MANKIND	0.0	0.5
CARDIAC	CORBIS D	Dec-24	TORRENT	1.0	1.5
<b>RESPIRATORY</b>					
RESPIRATORY	CODISTAR NF	Sep-23	MANKIND	35.6	39.3
RESPIRATORY	TRELEGY ELLIPTA	Feb-24	GSK	23.9	24.6
RESPIRATORY	ASTHAKIND PRO	Jan-24	MANKIND	7.7	9.0
<b>BLOOD RELATED</b>					
BLOOD RELATED	IRNY	Nov-23	DR. REDDYS	4.7	5.4
BLOOD RELATED	EFFCM	Oct-23	DR. REDDYS	24.1	29.8
BLOOD RELATED	HEMFER FCM	Nov-23	ALKEM	18.9	18.3
<b>VITAMINS / MINERALS / NUTRIENTS</b>					
VITAMINS / MINERALS / NUTRIENTS	CORCIUM XT	Nov-23	LUPIN	16.2	17.1
VITAMINS / MINERALS / NUTRIENTS	CENTRUM	Aug-23	GSK	8.3	11.2
VITAMINS / MINERALS / NUTRIENTS	SHELCAL PRO	Apr-24	TORRENT	3.0	3.8
<b>PAIN / ANALGESICS</b>					
PAIN / ANALGESICS	BETRECEP	Feb-24	PFIZER	13.0	17.5
PAIN / ANALGESICS	TOFATOP	Sep-23	ALKEM	7.8	9.1

SUPER GROUP	BRAND	LAUNCH DATE	CORPORATE	JUN-25	JUL-25
PAIN / ANALGESICS	SUMO ASP	Apr-25	ALKEM	4.6	4.8
PAIN / ANALGESICS	SUMO ACE	Aug-23	ALKEM	4.2	4.7
<b>ANTI-NEOPLASTICS</b>					
ANTI-NEOPLASTICS	VERSAVO PLUS	Jun-24	DR. REDDYS	24.5	18.9
ANTI-NEOPLASTICS	WOMAB	Jul-24	DR. REDDYS	13.5	21.8
ANTI-NEOPLASTICS	DENUB	Apr-24	ALKEM	6.5	6.0
ANTI-NEOPLASTICS	RIBAXA	Aug-24	DR. REDDYS	2.0	2.3
ANTI-NEOPLASTICS	LUPIPARP	Apr-24	LUPIN	1.2	1.2
ANTI-NEOPLASTICS	ENHERTU	Jan-24	ASTRAZENECA	0.3	0.4
<b>DERMA</b>					
DERMA	XYZAL UC	Jan-24	DR. REDDYS	3.3	3.5
DERMA	CUTICAPIL STEM ADVANCE	Nov-24	TORRENT	6.0	7.8
DERMA	STRANDZ	Aug-23	ERIS LS	1.1	1.6
<b>NEURO / CNS</b>					
NEURO / CNS	CANNEPSY	Dec-23	LUPIN	3.5	3.7
NEURO / CNS	DEXBUTRIN	Jun-24	TORRENT	0.7	0.8
NEURO / CNS	EPILAN P	Aug-24	LUPIN	1.3	1.5
NEURO / CNS	GABA Z NT	May-24	IPCA	1.0	1.2
<b>ANTI-INFECTIVES</b>					
ANTI-INFECTIVES	CEFBACT ES	Oct-23	CIPLA	4.4	5.3
ANTI-INFECTIVES	CLARIT (DR. REDDYS)	May-24	DR. REDDYS	2.0	2.6
ANTI-INFECTIVES	VORISPORE	Apr-24	ALKEM	1.3	0.9
<b>OPHTHAL / OTOLOGICALS</b>					
OPHTHAL / OTOLOGICALS	MENOHELP PLUS	Jan-24	MANKIND	9.3	9.6
OPHTHAL / OTOLOGICALS	MOXICIP LP	Sep-23	CIPLA	1.9	1.9
OPHTHAL / OTOLOGICALS	ALNESOL OD	Oct-24	ALKEM	0.9	0.8
<b>UROLOGY</b>					
UROLOGY	SILDOO M	Oct-24	DR. REDDYS	1.9	2.4
UROLOGY	URIMAX T	Apr-24	CIPLA	2.3	2.6
UROLOGY	MIRABLAD S	Sep-24	MANKIND	0.9	1.3
<b>GYNAECOLOGICAL</b>					
GYNAECOLOGICAL	DYDROSURE SR	Aug-24	ALKEM	7.2	7.6
GYNAECOLOGICAL	LUPIHOPE SR	Oct-24	LUPIN	3.4	4.7
GYNAECOLOGICAL	PX7	Jan-25	ERIS LS	0.2	0.2
<b>STOMATOLOGICALS</b>					
STOMATOLOGICALS	CHERRIO PLUS	Sep-24	DR. REDDYS	2.4	2.6
STOMATOLOGICALS	GUMLOC TOTAL	Sep-24	ABBOTT	1.1	1.2
<b>VACCINES</b>					
VACCINES	VAXIBOON	May-24	MANKIND	1.5	1.5
VACCINES	PNEUMOSHIELD	Feb-25	ABBOTT	0.6	3.6
<b>HORMONES</b>					
HORMONES	THYRONEED	Aug-23	MANKIND	2.2	2.2

Source: BOBCAPS Research, Pharमारack

**NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.**

## Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**

Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**

SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025**

Brand Name: **BOBCAPS**

Trade Name: **www.barodaetrade.com**

CIN: **U65999MH1996GOI098009**



Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

### Recommendation scale: Recommendations and Absolute returns (%) over 12 months

**BUY** – Expected return >+15%

**HOLD** – Expected return from -6% to +15%

**SELL** – Expected return <-6%

**Note:** Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

### Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

### General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.



#### Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

#### Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

#### Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

#### No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

#### Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.